The U.S. Food and Drug Administration (U.S. Food and Drug Administration) staff have raised concerns about the evidence supporting Moderna’s (Moderna) experimental flu vaccine mFlusiva ahead of a key advisory panel meeting in Washington. Regulators questioned the strength and completeness
